Lynch HT and Lynch JF. 2000. Hereditary nonpolyposis
colorectal cancer. Semin Surg Oncol 18:305.
Meigs JB, Barry MJ, Oesterling JE, and Jacobsen SJ.
1996. Interpreting results of prostate-specific antigen
testing for early detection of prostate cancer. J Gen
Intern Med 11:505.
Mikolajczyk SD, Grauer LS, Millar LS, Hill TM, Kumar
A, Rittenhouse HG, Wolfert RL, and Saedi MS.
1997. A precursor form of PSA (pPSA) is a compo-
nent of the free PSA in prostate cancer serum.
Urology 50:710.
Morgan TO, Jacobsen SJ, McCarthy WF, Jacobson DJ,
McLeod DG, and Moul JW. 1996. Age-specific refer-
ence ranges for serum prostate-specific antigen in
black men. N Engl J Med 335:304.
Moss SM and Melia J. 1998. Screening for prostate
cancer: the current position. Br Med Bull 54:791.
Nollau P and Wagener C. 1997. Methods for detection of
point mutations: performance and quality assessment.
Clin Chem 43:1114.
Odell WD. 1997. Endocrine/metabolic syndromes of
cancer. Semin Oncol 24:299.
Oesterling JE, Jacobsen SJ, Chute CG, Guess HA,
Girman CJ, Panser LA, and Lieber MM. 1993. Serum
prostate-specific antigen in a community-based
population of healthy men. JAMA 270:860.
Pantel K and von Knebel Doeberitz M. 2000. Detection
and clinical relevance of micrometastatic cancer cells.
Curr Opin Oncol 12:95.
Partin AW, Carter HB, Chan DW, Epstein JI, Oesterling
JE, Rock RC, Weber JP, and Walsh PC. 1990.
Prostate specific antigen in the staging of localized
prostate cancer: influence of tumor differentiation,
tumor volume and benign hyperplasia. J Urol
143:747.
Partin AW, Kattan MW, Subong ENP, Walsh PC, Wojno
KJ, Oesterling JE, Scardino PT, and Pearson JD.
1997. Combination of prostate-specific antigen, clini-
cal stage, and Gleason score to predict pathological
stage of localized prostate cancer. A multi-institutional
update. JAMA 277:1445.
Polascik TJ, Oesterling JE, and Partin AW. 1999.
Prostate specific antigen: a decade of discovery—what
we have learned and where we are going. J Urol 162:
293.
Ponder B. 1997. Genetic testing for cancer risk. Science
278:1050.
Ried T, Knutzen R, Steinbeck R, Blegen H, Schrock E,
Heselmeyer K, du Manoir S, and Auer G. 1996.
Comparative genomic hybridization reveals a specific
pattern of chromosomal gains and losses during the
genesis of colorectal tumors. Genes Chromosomes
Cancer 15:234.
Rittenhouse HG, Finlay JA, Mikolajczyk SD, and Partin
AW. 1998. Human kallikrein 2 (hK2) and prostate-
specific antigen (PSA): two closely related, but
distinct, kallikreins in the prostate. Crit Rev Clin Lab
Sci 35:275.
Scarpa A and Achille A. 1997. Molecular techniques in
hematopathology. Leuk Lymphoma 26 (Suppl 1):77.
Schmid HP, McNeal JE, and Stamey TA. 1993. Clinical
observations on the doubling time of prostate cancer.
Eur Urol 2:60.
Sell S. 1980.
Cancer Markers: Developmental and Diag-
nostic Significance.
Humana Press, New York.Stamey
TA, Yang N, Hay AR, McNeal JE, Freiha FS, and
Redwine E. Prostate-specific antigen as a serum
marker for adenocarcinoma of the prostate. N Engl J
Med 317:909.
Simak R, Madersbacher S, Zhang ZF, and Maier U.
1993. The impact of ejaculation on serum prostate
specific antigen. J Urol 150:895.
Stamey TA, Yang N, Hay AR, McNeal JE, Freiha F, and
Redwine EA. 1987. Prostate-specific antigen as a
serum marker for adenocarcinoma of the prostate.
New Engl J Med 317:909.
Stenman U-H, Leinonen J, and Zhang W-M. 1995.
Standardization of PSA determinations. Scand J Clin
Lab Invest 55 Suppl 221:45.
Stenman U-H, Leinonen J, Zhang W-M, and Finne P.
1999. Prostate-specific antigen. Semin Cancer Biol
9:83.
Svetec D and Thompsom IM. 1998. PSA screening-
current controversy. Ann Oncol 9:1283.
Tisdale MJ. 1997. Biology of cachexia. J Natl Cancer
Inst 89:1763.
Vasen HFA, Wijnen JT, Menko FH, Kleibeuker JH, Taal
BG, Griffioen G, Nagengast FM, Meijers-Heijboer
EH, Bertario L, Varesco L, Bisgaard ML, Mohr J,
Fodde R, and Khan PM. 1996. Cancer risk in families
with hereditary nonpolyposis colorectal cancer
diagnosed by mutation analysis. Gastroenterology
110:1020.
Werner M, Wilkens L, Aubele M, Nolte M, Zitzels-
berger H, and Komminoth P. 1997. Interphase cytoge-
netics in pathology: Principles, methods, and
applications of fluorescence in situ hybridization
(FISH). Histochem Cell Biol 108:381.
Winkel P, Bentzon MW, Statland BE, Mouridsen H, and
Sheike ). 1982. Predicting recurrence in patients with
breast cancer based on cumulative laboratory results.
A new technique for the application of time series
analysis. Clin Chem 28:2057.
Woolf SH and Rothemich SF. 1999. Screening for
prostate cancer: the roles of science, policy, and
opinion in determining what is best for patients. Annu
Rev Med 50:207.
Yamauchi H, Stearns V, and Hayes DF. 2001. When is a
tumor marker ready for prime time? A case study of
c-
erb
B-2 as a predictive factor in breast cancer. J Clin
Oncol 19:2334.
Cancer
11-21
